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Background: Thoracic impedance (TI) influences the success of external cardioversion (ECV) or defib-
rillation because current intensity traversing the heart is inversely related to TI. Experimental data suggest
that TI decreases after multiple shocks. We undertook a clinical study to determine changes of TI values
in patients with atrial fibrillation or flutter requiring ECV.
Methods:We enrolled 222 consecutive patients (age 73 ± 11 years; males 67%; body weight 75 ± 13 kg)
who underwent ECV between January 2004 and February 2007. Biphasic shocks were delivered through
adhesive pads placed in the anteroposterior position. The initial energy was set at 1 J/kg, with progressive
increases up to amaximum of 180 J in case of failure. In the last 39 elective patients, plasma concentration
of interleukin-6 (IL-6) and tumor necrosis factor (TNF)-α were determined before and 6 hours after ECV.
Results: Sinus rhythm was restored in 202 patients (91.0%). Of these, 155 (69.8%) required more
than one shock (on average, 2.5 ± 1.5 shocks/patient). Final values of energy and peak current intensity
were 136 ± 47 J and 50 ± 14 A, respectively. TI decreased significantly by 6.2% from baseline after
≥2 shocks (P < 0.001). The absolute reduction was correlated with baseline TI, number of delivered
shocks, and hemoglobin oxygen saturation. IL-6 and TNF-α increased with ECV (P < 0.001 and P = 0.014,
respectively).
Conclusions: TI decreases significantly after multiple shocks, possibly by activation of acute inflamma-
tion. (PACE 2009; 32:371–377)
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Introduction
The efficacy of external cardioversion (ECV)
for atrial fibrillation (AF) and flutter (AFL) is re-
lated to the intensity of current traversing the tho-
rax.1,2 Barring technical factors involving the de-
fibrillator and electrodes, thoracic impedance (TI),
an index of electrical resistance, is the most im-
portant physical factor conducive to ECV success
because it is inversely related to the current am-
plitude delivered to the heart.1,2
Previous studies have investigated TI demon-
strating a correlation with body weight, chest size,
repeated shocks, size, and contact pressure of pad-
dles.1,3,4 However, those studies were conducted
applying an electrical current to the chest of an-
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imal models and humans during the defibrilla-
tor charge cycle, before the effective defibrillat-
ing shock was delivered, or using special equip-
ments designed for research purposes only.1,3–6
Recently, we showed that TI in patients under-
going ECV of AF and AFL was directly related to
body mass index, female gender, and hemoglobin
concentrations, and inversely related to the pres-
ence of chronic heart failure (CHF).7
TI values might play a significant role in
modifying the conceptual approach to defibril-
lation from an energy-based to a current-based
procedure, according to the recommendations
contained in the 2005 American Heart Associa-
tion Guidelines for Cardiopulmonary Resuscita-
tion and Emergency Cardiovascular Care.8 This
switch might encourage clinicians to select more
appropriate values of current intensity rather than
energy, with the potential of reducing the risk of
complications and increasing efficacy.8 On this ba-
sis, we now determined whether multiple shocks,
delivered by a defibrillator commonly used in clin-
ical practice, for ECV of AF and AFL, are associ-
ated with TI reduction and whether acute inflam-
mation may justify this phenomenon.
C©2009, The Authors. Journal compilation C©2009 Wiley Periodicals, Inc.
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Methods
Patients
The study consisted of 222 consecutive pa-
tients who underwent elective or emergency ECV
of AF or AFL, between January 2004 and Febru-
ary 2007. The study was approved by the insti-
tutional review committee and all subjects gave
informed consent. There were no exclusion crite-
ria. Elective ECV was carried out in patients with
persistent or permanent AF after at least 4weeks of
oral anticoagulation therapywith the international
normalized ratio (INR) values in the 2–3 range.9
An echocardiogram was performed in all patients.
Routine blood tests, iron balance, erythrocyte sedi-
mentation rate (ESR), C-reactive protein, pro-brain
natriuretic peptide level, and hepatic and thyroid
function were evaluated in each patient. In the
case of hyperthyroidism, ECV was postponed un-
til normalization of thyroid function.
Patients were evaluated according to a pro-
tocol based on American College of Cardiology/
American Heart Association key data elements
and definitions for measuring the clinical man-
agement and outcomes of AF.10 Chronic obstruc-
tive pulmonary disease (COPD) and diabetes mel-
litus were diagnosed using the criteria outlined
by the National Heart, Lung, and Blood Insti-
tute and World Health Organization11 and the
American Diabetes Association,12 respectively.
The following cardiac diagnoses were considered
as possible causes of AF: (1) coronary heart dis-
ease (acute/healed myocardial infarction, unsta-
ble angina) in the absence of CHF, (2) stage C
or D CHF13 of any etiology, (3) significant valvu-
lar dysfunction in the absence of overt CHF,14,15
(4) hypertension (systolic/diastolic arterial pres-
sure ≥140/90 mmHg, or antihypertensive ther-
apy),16 and (5) lone AF in the absence of clini-
cal or echocardiographic evidence of any cardiac
disease.
An arterial blood sample was drawn to mea-
sure pH, PaO2, PaCO2, hemoglobin oxygen sat-
uration, and electrolytes immediately before the
procedure. Total creatine phosphokinase (CPK),
CPK-myocardial band (CPK-MB), myoglobin, and
troponin I concentrations were measured at base-
line and 6 hours after ECV to estimate cardiac or
muscular damage due to the procedure.
External Cardioversion
ECV was performed under general anesthesia
induced through an infusion of sodium thiopen-
tal or propofol. Anesthesia lasted about 5 minutes,
while maintaining hemoglobin saturation at about
100% with an oxygen mask. ECV was performed
using a Defigard 5000 cardioverter/defibrillator
(Schiller/ESAOTE, Florence, Italy). Shocks were
applied via two oval adhesive pads, 78 cm2 each,
Figure 1. Graphic representation of the multipulse
biowave biphasic waveform. The lengths of the posi-
tive and the negative components are 4.2 and 3.2 ms,
respectively. The waveform is composed by a train of
high-frequency isolated impulses separated by pauses.
The highest amplitude of the impulse train is the peak
current intensity, while the sum of the energies of each
impulse is the cumulative energy of the shock.
that were always placed in anteroposterior po-
sition.17,18 The delivered biphasic shock (Multi-
pulse Biowave, Schiller AG, Baar, Switzerland)
consisted of a positive and negative component
lasting 4.2 and 3.2 ms, respectively, which were
separated by a short interval of 0.4 ms, in which
no energy was released (Fig. 1). The waveform
was not continuous and was composed by a train
of isolated impulses generated at high frequency
(5,000 Hz), separated by pauses. The highest am-
plitude of the impulse train was the peak current
(A) of the shock, and the sum of the energies of
each impulse was the cumulative energy (J) deliv-
ered (Fig. 1). The ratio between the length of each
segment impulse and the interval to the next one,
called the duty cycle, was variable, to dynamically
adapt the energy of the shock to the thoracic elec-
trical impedance (ohm), calculated by amicrocom-
puter during the very first part of the shock from
the current intensity between the twopads.19 Com-
pared to other biphasic waveforms, more com-
monly used in clinical practice, this pulsed wave-
form has a big advantage: due to the duty cycle,
an effective current intensity can be reached with
lower cumulative energy levels, minimizing car-
dioversion side effects. Indeed, the pulse provides
a high efficiency, related to the high current inten-
sity, with a reduced risk level, related to the low
energy delivered.19,20
After each shock, the values of cumulative en-
ergy, peak current intensity, and thoracic electri-
cal impedancewere recorded. The value of the first
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shock of about 1 J/kg of body weight was rounded
to the closest multiple of 10. If AF persisted, the
energy of the subsequent shocks was increased to
130 and 180 J (maximum energy) for the second
and third shock, respectively. If the arrhythmia
persisted, two other 180-J shocks were delivered,
after which no further attempts were made except
in patients not pretreated pharmacologically, in
whom two final 180-J shocks were attempted af-
ter they were given an intravenous antiarrhythmic
agent.9,21 ECVwas considered successful when pa-
tients were discharged in sinus rhythm.
Plasma Concentrations of Inflammatory
Cytokines
In the last 39 patients who underwent elec-
tive ECV, bloodwas collected to determine plasma
concentrations of interleukin-6 (IL-6) and tumor
necrosis factor-α (TNF-α), at baseline and 6 hours
after ECV.
Blood samples were collected in EDTA tubes
and centrifuged at 4◦C for 15 minutes, at 1000×g,
within 30 minutes. Plasma was stored at −80◦C
until IL-6 and TNF-α concentration were mea-
sured, using commercially available ELISA kits
(UltraSensitive, BioSource International, Camar-
illo, CA, USA and Quantikine HS, R&D Systems,
Abingdon, UK, respectively).
Statistical Analysis
Data collection and statistical analysis were
performed using SPSS for Windows 14.0 (SPSS
Inc., Chicago, IL, USA). Continuous variables are
expressed as mean ± standard deviation, or as
median value and range when not normally dis-
tributed (Kolmogorov-Smirnov test). Categorical
variables are expressed as percentages.
Continuous variableswere compared between
two or more groups of patients with Student’s t-
test or one-way analysis of variance, respectively,
while their correlation was assessed with univari-
ate linear regression analysis. Changes over time
were evaluated with general linear models (GLM)
for repeated measures, in which we entered all
consecutive data for each patient. Nonparametric
tests were also used to test variables with large
standard deviations. The relation between categor-
ical variables was studied with χ2 test.
Bivariate linear regression models or GLM
were used to test the association of continuous
or categorical clinical variables with changes in
TI, while adjusting for baseline TI, which was in
fact directly correlated to its variations (see the Re-
sults section). To identify the independent predic-
tors of TI changes, variables that were significant
at bivariate analysis were then entered into mul-
tivariate linear regression models, with backward
deletion (P out >0.10).
A P value < 0.05 was considered as statisti-
cally significant.
Results
Patients
Table I outlines the main demographic and
clinical characteristics of the 222 patients (190
[85.6%] had AF and 32 [14.4%] AFL). The me-
dian AF or AFL duration was 2.5 months (range 1
day to 20 years). Based on arrhythmia duration, pa-
tients were stratified into three groups: ≤48 hours
(16.7%), 48 hours to 6 months (68.1%), and >6
months (15.3%).
Oral anticoagulation was used in 85.4% of pa-
tients (Table I). Amiodarone was the single most
frequently prescribed antiarrhythmic agent, used
in 52.3% of patients before ECV.
Efficacy of ECV
ECV restored sinus rhythm in 202 of 222 pa-
tients (91.0%), with an early, in-hospital relapse
occurring in 10 of 202 cases (5.0%). The mean
number of shocks and mean final energy were
2.5 ± 1.5 and 136 ± 47 J, respectively. Multiple
shocks were used in 155 (69.8%) patients, while a
one-shock procedure was effective in the remain-
ing 67 patients. In patients with multiple shocks,
the median time interval between the first and the
last shock was 2 minutes (range 1–239), and the
total delivered energy 429 ± 280 J, corresponding
to 5.7 ± 3.5 J/kg of body weight (P < 0.001 vs one-
shock patients: 1.2 ± 0.5 J/kg of body weight). The
related peak current intensity was 148 ± 78 A,
corresponding to 2.0 ± 1.0 A/kg of body weight
(P < 0.001 vs one-shock patients: 0.5 ± 0.2 A/kg
of body weight).
Multiple shocks were associated with a sig-
nificant rise of plasma myoglobin, which was not
observed in patients receiving only one shock (>1
shock: +50 ± 132 ng/mL from baseline vs 1 shock:
−1 ± 17 ng/mL from baseline, P < 0.001). Changes
in total CPK, CPK-MB, and troponin I were not de-
tected in the two groups of patients.
No ECV-related complications were ob-
served.
ECV and Thoracic Impedance
Baseline TI was 57.3 ± 11.9 ohm. The use
of multiple shocks significantly reduced TI from
57.7 ± 11.4 ohm at first shock to 54.1 ± 10.8 ohm
at last shock (P < 0.001), with such a reduction
occurring in 146 of 155 (94.2%) multiple-shock
patients. A retrospective analysis indicated that
the power of these observations was>99.9%, with
two-tailed α = 0.05. Multiple, sequential shocks
yielded additive effects on TI, which decreased by
6% and 13% from baseline (P < 0.001 for both
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Table I
Demographic and Clinical Characteristics
Variables Range
Age (years) 73 ± 11 25–95
Males (%) 66.7
Weight (kg) 75 ± 13 42–120
Height (cm) 169 ± 9 138–192
History of smoking 54.3
(present/past, %)
Comorbid conditions
Hypertension (%) 77.5
Chronic heart failure (%) 47.3
Valvular heart disease
Aortic (%) 13.1
Mitral (%) 46.8
Tricuspid (%) 4.1
Myocardial infarction (%) 29.7
History of cardiac
surgery (%) 23.0
Diabetes (%) 16.2
COPD (%) 9.5
Echocardiographic data
LV ejection fraction (%) 48 ± 15 15–72
LAD (mm) 47 ± 6 34–60
LAD > 40 mm (%) 76.2
Blood tests
Creatinine (mg/dL) 1.3 ± 0.5 0.7–4.70
Hemoglobin (Hb, g/dL) 13.8 ± 1.6 9.4–17.6
Pro-BNP (pg/mL) 1,596 ± 1499 191–9,435
O2 Hb saturation (%) 97 ± 2 87–100
TSH (mU/L) 2.79 ± 6.37 0.05–76.00
Drug therapy
Oral anticoagulation (%) 85.4
Class I C antiarrhythmic
agents (%) 12.1
β-blocking agents (%) 44.2
Amiodarone (%) 52.3
Ca-antagonists (%) 17.1
Digoxin (%) 45.7
ACE inhibitors/ anti-
ATII (%) 82.4
Diuretics (%) 52.3
Statins (%) 24.1
Abbreviations: COPD = chronic obstructive pulmonary disease;
LV = left ventricle; LAD = left atrium diameter; anti-ATII =
angiotensin II receptor blockers; BNP = brain natriuretic peptide;
ACE = angiotensin-converting enzyme.
comparisons) after three and six or more shocks,
respectively (Fig. 2).
The absolute change in TI was directly corre-
lated to its baseline value (β ± SE = 0.08 ± 0.02
ohm for 1 ohm of baseline TI, r = 0.348, P <
0.001). A bivariate analysis adjusted for baseline
Figure 2. Percentage changes of thoracic impedance
(TI) during ECV assuming 100% as the starting value.
Each line refers to the group of patients treated with the
same number of shocks. Each point of every line repre-
sents the percentage value of TI observed after the shock
indicated on the axis versus the baseline value. For each
line the numeric value of last percentage TI is reported.
In general linear models for repeated measures the P
values related to each line were all <0.001.
TI revealed that the maximal reduction in TI was
smaller (P = 0.033) in the presence of COPD, and
greater with increasing hemoglobin oxygen satu-
ration (r = 0.397, P = 0.011; Fig. 3), number of
shocks (r = 0.625, P < 0.001), time interval be-
tween first and last shock (r = 0.478, P < 0.001),
total amount of delivered energy (r = 0.564, P <
0.001), and total amount of peak current intensity
(r= 0.597, P< 0.001). The length of AF, its cardiac
causes, and all the other clinical variables did not
show any statistical association with TI reduction.
Atmultivariate analysis after backward deletion of
Figure 3. Relationship between hemoglobin oxygen sat-
uration (Hb O2 Sat) at baseline, before O2 supplementa-
tion, and changes in thoracic impedance (TI) after the
last shock. The broken line refers to no variations in
TI. β, R, and P values derive from the bivariate model,
adjusted for baseline TI.
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Table II
Multivariate Predictors of Changes in Transthoracic Impedance
β ± SE 95% CI P Value
Constant –22.42 ± 8.92 –40.05 to –4.79 0.013
Hb O2 saturation (%) 0.21 ± 0.09 0.02 to 0.39 0.032
Baseline TI (ohm) 0.06 ± 0.02 0.03 to 0.09 <0.001
Number of shock (n) 0.94 ± 0.12 0.70 to 1.18 <0.001
Linear regression analysis; r = 0.638, P < 0.001.
β = coefficient of changes in thoracic impedance (dependent variable) for unitary change in independent variable; 95%CI = 95%
confidence intervals. Variables backward deleted by the model: COPD (P = 0.271); total amount of peak current intensity (P = 0.610);
time elapsed between the first and the last shock (P = 0.111).
COPD (P = 0.271), total amount of peak current in-
tensity (P = 0.610) and time interval between first
and last shock (P = 0.111), the reduction in TI cor-
related directly with baseline TI (P < 0.001), num-
ber of shocks (P < 0.001), and hemoglobin oxygen
saturation (P = 0.032) (Table II). More in de-
tail, TI decreases of 0.94 ohm for each further
shock received by the patient and of 0.21 ohm for
each percentage of baseline hemoglobin oxygen
saturation.
Changes in TI were still detectable at 239min-
utes since the last shock. However, in five patients
with early relapse who underwent a second ECV
after 24 hours, TI had returned to baseline values
(24-hour TI 56.2 ± 19.9 ohm vs baseline TI 57.4 ±
22.1 ohm, P = 0.438).
ECV and Cytokines
Six hours after ECV, mean IL-6 and TNF-
α concentrations were markedly increased from
normal baseline values (Fig. 4). Such an increase
was evident in 66.7% and 75.7% of patients,
respectively.
Figure 4. Changes of plasma IL-6 and TNF-α concentra-
tions from baseline to 6 hours after external cardiover-
sion (ECV). * Wilcoxon test P value.
Discussion
This study demonstrates thatmultiple electric
shocks during ECV induce a significant TI reduc-
tion. This phenomenon is linear, implying that the
greater the number of shocks, the greater the TI re-
duction. The decrease of TI is rapidly reversible,
as demonstrated in patients who underwent a sec-
ond ECV 24 hours after the first procedure.
Several factors can influence TI: (1) the di-
mension, position, and distance between the pads,
(2) the chemical characteristics of the gel interfac-
ing with the skin, and (3) the phase of respiration
during which the shock occurs.1–3,22 These vari-
ables were always kept constant in our study. In
fact, we always used the same type of defibrillator,
with preprepped adhesive pads always placed in
the anteroposterior position. Finally, respiration
should not have affected TI, given that ECV was
carried out during apnea after the induction of gen-
eral anesthesia. Therefore, our data suggest that the
TI changes reflect transient modification of tissue
conductance. The reproducibility of the observa-
tion supports this mechanism because stratifying
patients according to the number of shocks yielded
parallel TI changes (Fig. 2).
Factors Influencing Transthoracic Impedance
Themultivariate predictors of TI reduction in-
cluded baseline TI, number of electric shocks, and
hemoglobin oxygen saturation. The direct correla-
tion between TI reduction and hemoglobin oxygen
saturation might be ascribed, at least in part, to co-
linearity with COPD, a chronic condition known
to affect TI because of reduced muscular mass, in-
creased proportion of fat, and less vascularized
lung tissue.23 Indeed, in our series, COPD patients
had a lower reduction of TI than other patients.
IL-6 and TNF-α, two important markers of in-
flammation, were measured in a limited subset of
patients. Both cytokines are able to activate sev-
eral intracellular pathways, leading to an increase
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of acute phase mediators and modulation of vas-
cular permeability.24 We found a significant ECV-
mediated increase in plasma concentrations of IL-
6 and TNF-α. These data are particularly relevant
because they were collected only for elective ECV,
excluding the possible influence of acute diseases
on inflammatory markers. IL-6 was under the de-
tectable threshold level at baseline in 84.6% of pa-
tients but 6 hours after ECV, its concentration was
measurable in 71.8% of patients. Similarly, TNF-
α levels increased in 75.7% of patients after ECV.
These findings are consistent with the hypothesis
that TI decreases after multiple shocks possibly by
activation of acute inflammation.
Limitations
Cytokines were measured only in a relatively
small subgroup of patients. The relative skewed
distribution of time elapsed between the first and
the last shock did not allow us to uncover the full
effect of acute inflammation on TI changes. More-
over, the increase of IL-6 concentrations could be
dampened by the fact that baseline values of the
molecule were under the detectable limit in a ma-
jority of subjects.
Clinical Implications
In the year 2000, the Guidelines on Cardiopul-
monary Resuscitation left an unresolved issue,
whether or not after an unsuccessful first defib-
rillation attempt it was necessary to increase the
energy level for a second attempt.2 Two main fac-
tors support the proposition of maintaining the
same energy level: a statistical consideration re-
garding the relatively high probability of success
of the procedure2; alternatively, an increase in
transthoracic current intensity mediated by a TI
decrease.1–3 The 2005 Guidelines on Cardiopul-
monary Resuscitation overcame, at least in part,
this issue, indicating the need to start with the
highest possible energy (360 J) with monopha-
sic defibrillators, and with 150–200 J when using
biphasic waveforms.8 Although this approachwill
resolve the arrhythmia in more than 90% of pa-
tients, there are still about 10% who will need a
further shock8 for whom a decrease in TI may fa-
cilitate the restoration of an effective rhythm.
The results of this study support the concept
of a shock-related TI reduction.
TI showed a progressive 4% decline after the
second attempt, and 9% and 13% decline after
the fifth and the sixth attempt, respectively. Even
though this result is quantitatively inferior to the
15.8% TI reduction reported by Deakin et al., by
applying a 12-kg force to the defibrillator paddles
placed in anterolateral position, we must empha-
size that only 14% of operators were able to reach
this target pressure.25
Conclusion
Multiple shocks for ECV of AF andAFL signif-
icantly reduce TI values. Multiple shocks activate
acute inflammation with a subsequent increase of
vascular permeability and tissue fluid accumula-
tion that might contribute to TI changes. TI de-
crease is directly related to the number of shocks,
as well as the energy and current intensity. In fact,
when more than one ECV attempt is necessary, TI
reduction may allow a higher and more effective
current intensity with a subsequent shock of the
same strength. Indeed, the 2000 and 2005 Guide-
lines on Cardiopulmonary Resuscitation both un-
derscore the importance of TI and encourage a
transition from a more generic energy-based to a
specific current-based approach for defibrillation
and ECV.2,8 Our results favor this recommenda-
tion. Further studies are necessary to better define
the role of clinical factors and mediators of acute
inflammation on TI variations.
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